Adma Biologics Inc · NASDAQ:ADMA
Adma Biologics — Investor Presentation (October 2019)
22 slides from Adma Biologics's investor presentation, Oct 2, 2019
Slide 1: Groundbreaking Immunotechnology, One Connection at a Time
ADMA d BIOLOGICS ADMA Biologics | — GROUNDBREAKING IMMUNOTECHNOLOGY, ONE CONNECTION ATA TIME October 2019 Nasdaq: ABMA
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS s, Inc. (“we,” “our” This presentation cont ‘or the “Company”), including, without limitation, statements that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “target,” “anticipate,” “plan,” “expe
Slide 3: Who We Are
nnn WHO WE ARE = ADMA Biologics is a vertically integrated commercial biopharmaceutical company committed to manufacturing, marketing and developing specialty plasma-derived products for the immune-compromised and other patients at risk for infection. It is our devotion to these underserved populati
Slide 4: ADMA Biologics - Corporate Background
NN ADMA ADMA BIOLOGICS —- CORPORATE BACKGROUND \ ADMA Biologics was founded to address unmet needs for immune compromised patient populations We understand the commitment and resources required to operate an effective manufacturing organization operating in cGMP compliance We are committed to provid
Slide 5: Commercial Company
) COMMERCIA\ _ COMPANY J + Operates an FDA-approved 400,000L capacity plasma therapeutics manufacturing facility with potential for expansion «Products acquired: Nabi-HB® (Hepatitis B IG, Human) and BIVIGAMs (IVIG, Human) +Control all aspects of drug substance manufacturing, regulatory compliance an
Slide 6: Experienced Management Team and Board of Directors
EXPERIENCED MANAGEMENT TEAM AND BOARD OF DIRECTORS pxame SELECTED CURRENT OR PAST AFFILIATIONS Adam Grossman v y =e Founder, President, | | | 2 G nhs ‘American CEO & Director Medimmune GENESIS» {Genesis Bl-Pharmaceuticals. ne [NATIONAL MOSPITAL SPECIALTIES Red Cross Executive Vico Prsidert BioSNJ ¥C
Slide 7: Blood & Plasma Composition
BLOOD & PLASMA COMPOSITION ed Blood Contains: Plasma, Red Cells, White Cells and Platelets Plasma Contains: Protein and Water Plasma Proteins Contain Many Therapeutic Benefits: ¢ Intravenous immunoglobulin (IVIG) is made from a key therapeutic protein in plasma: Immunoglobulin (IgG) * IgG = naturall
Slide 8: ADMA Is One of a Few Commercial Manufacturers of Plasma Products
ADMA IS ONE OF A FEW COMMERCIAL MANUFACTURERS OF PLASMA PRODUCTS AND SPECIALTY IMMUNE GLOBULINS IN THE U.S. Successful plant inspections and drug approvals received Track record of receiving FDA approval for plasma collection centers ~400,000L annual capacity plasma fractionation and purification pl
Slide 9: Plasma Products Portfolio Overview & Pipeline
Semel Market Opportunities , PLASMA PRODUCTS PORTFOLIO OVERVIEW & PIPELINE IMMUNE GLOBULIN INTRAVENOUS seeat-5B . BIVIGAM Nabi ASCENIV Chunar: te igud (Huma, 10% Loui ne tui a) ‘Nasdaq: ADMA.
Slide 10: Growth Drivers: Plasma IG Market Is Sizeable & Growing
GROWTH DRIVERS: PLASMA IG MARKET IS SIZEABLE & GROWING \ Gazer IMMUNE GLOBULIN (IG or IVIG) is a pooled plasma product from healthy plasma donors, containing a range of polyclonal antibodies against common pathogens IG IS USED TO IG WIDELY IG UTILIZATION TREAT A WIDE MARKETED INCREASING VARIETY OF I
Slide 11: Commercial Products: Brands in an Expanding IG Market
COMMERCIAL PRODUCTS: 3 BRANDS IN AN EXPANDING IG MARKET ASCENIV TWMUNE GLOBULIN INTRAVENOUS (AUMAN) 105% (1UID ASCENIV™ (Immune Globulin Intravenous - sira, Human) FDA-APPROVED PROTECTION AGAINST SERIOUS INFECTIONS + Indicated for the treatment of patients with Pl + Contains a wide spectrum of polyc
Slide 12: IG Is Widely Used and Reimbursed
IG IS WIDELY USED AND REIMBURSED FDA-Approved Uses* Possible Additional Reimbursed Evidence-Based Uses Primary immunodeficiency (PI) Acquired red cell aplasia Multiple myeloma Rasmussen's syndrome Multifocal motor neuropathy Bone marrow transplantation Myasthenia gravis sae transplant from liver i i
Slide 13: PI Is a Significant Market Opportunity for ADMA
PI 1S A SIGNIFICANT MARKET OPPORTUNITY FOR ADMA Class Est. Incidence (U.S.) _| Target Population Population Numbers ~250,000 PI PATIENTS in theu.s. ~50% are treated with IG THE ADMA PORTFOLIO OF IG PRODUCTS. offers alternatives and can help treat major subsets of the PI population At present, IVIG a
Slide 14: ADMA Is an Advocate for the PI Patient
ADMA IS AN ADVOCATE FOR THE PI PATIENT GaReY Different Patient Types Present with Different Risks for Infection Risk Factors for Infection in PI Risk Factors for Infection in Pl + Type and severity of immune deficiency + Age + Impaired pulmonary function ¥ Bronchiectasis v Asthma Y History of respir
Slide 15: Discover Immunotechnology
DISCOVER T| IMMUNOTECHN 14
Slide 16: ADMA Pipeline
ADMA PIPELINE OD Potential Target Populations for ASCENIV™ As previously disclosed, we believe the FDA approval of ASCENIV™ better positions ADMA to further its mission to evaluate ASCENIV™ in immune-compromised patients infected with or at-risk for Respiratory Syncytial Virus (RSV) infection. + HSC
Slide 17: Expanding Product Portfolio with Additional Specialty IG Products
By leveraging ADMA’s IP, know-how and expertise, we may seek to expand our product portfolio with additional specialty IG products by building upon our core competency of identifying high-titer plasma donors and plasma products manufacturing expertise
Slide 18: ADMA Products, Pipeline and Ongoing R&D
ADMA PRODUCTS, PIPELINE AND ONGOING R&D R&D Activity / Other BLA FDA Approved / Product / Candidate Information Submitted Marketed Pediatric Indication / MEAL Manufacturing capacity a Human, Immunoglobulin intravenous expansion Nabi-HB® Hepatitis B, Hyperimmune Globulin IM formulation ——————® ASCENI
Slide 19: Milestones & Financial Highlights
BIOLOGICS » ' b Milestones.& Financial Highlights Nasdaq: ADMA
Slide 20: Recent Milestones & Future Objectives
RECENT MILESTONES & FUTURE OBJECTIVES RECENTLY COMPLETED ¥ Relaunched BIVIGAM® with first commercial sales in the U.S. v Obtained FDA approval for BIVIGAM® PAS v ASCENIV™ (formerly RI-002) FDA approved v New license issued/transfered for manufacturing plant, BIVIGAM® and Nabi-HB® (#2019) Y Successfu
Slide 21: Financial Information
FINANCIAL INFORMATION Financial Summary: 6/: 9 Results Cash and cash equivalents: $73.6M Total assets $143.3M Total liabilities $96.4M Total stockholders’ equity $46.9M Revenue (6 months) $10.1M Common stock outstanding 59.3M Fully diluted common stock outstanding 67.1M *Additional funding commitmen
Slide 22: FDA Licensed Facility
FDA LICENSED FACILITY PROCESS VALIDATION COMMERCIAL PRODUCTS PIPELINE USING IMMUNOTECHNOLOGY IP CONTRACT MANUFACTURING & TESTING PLASMA COLLECTION VERTICAL INTEGRATION CURRENT CONTRACT FOR ABILITY TO SUPPLY A PORTION OF THE GIYEERIMMUNE | GLOBULIN CMO INTERNAL NEEDS AND SELL TO 3 + FULL QC LABORATOR
ADMA Biologics — Investor Presentation (October 2019) on 6ix